Core Viewpoint - Envoy Medical has secured additional patents for its innovative cochlear implant technologies, enhancing its intellectual property portfolio and positioning in the hearing health market [1][2][4]. Patent Developments - The US Patent & Trademark Office issued US Pat. No. 12,214,195 on February 4, 2025, for an Implantable Cochlear System with Inner Ear Sensor, which includes a cochlear electrode, stimulator, inner ear sensor, and signal processor [2]. - US Pat. No. 12,233,256 will be issued on February 25, 2025, focusing on adjustable stereo cochlear implant systems that allow for independent volume adjustments for each subsystem [3]. - The Japanese Patent Office granted three new patents on December 2 and 3, 2024, related to cochlear implant subsystems and lead characterization, all under the title Implantable Cochlear System with Integrated Components and Lead Characterization [4]. - The Hong Kong Patent Office granted HK Patent No. HK40097814 on January 3, 2025, for Programming of Cochlear Implant Accessories, facilitating easier pairing of accessory devices to cochlear implant systems [5]. Product Overview - The Acclaim Cochlear Implant is highlighted as a first-of-its-kind fully implanted device designed to address severe to profound sensorineural hearing loss, leveraging the natural anatomy of the ear for sound capture [6][7]. - The Acclaim CI received Breakthrough Device Designation from the FDA in 2019, indicating its potential significance in the market [8].
Envoy Medical Secures Additional Patent Protection for Its Growing Patent Portfolio